Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy

Table 4

FRAX score in the prediction of vertebral fracture in men with prostate cancer.

		All Subjects		Non-African-American		African-American
		(N = 78; vertebral		(N = 59; vertebral		(N = 19; vertebral
		Fx = 22/78 = 24.4%)		Fx = 18/59 = 31%)		Fx = 4/19 = 21%)
		ROC AUC	95% CI	ROC AUC	95% CI	ROC AUC	95% CI
FRAX (Hip) without BMD	before X-ray	0.55	0.39–0.70	0.59	0.42–0.77	0.42	0.15–0.70
	after X-ray	0.66	0.53–0.78	0.63	0.47–0.78	0.72	0.42–1.00
FRAX (Osteo) without BMD	before X-ray	0.59	0.43–0.75	0.66	0.48–0.84	0.50	0.22–0.78
	after X-ray	0.74	0.62–0.85	0.73	0.59–0.87	0.94	0.82–1.00
FRAX (Hip) with BMD	before X-ray	0.53	0.37–0.69	0.60	0.42–0.79	0.64	0.18–1.00
	after X-ray	0.66	0.52–0.80	0.63	0.47–0.79	0.74	0.39–1.00
FRAX (Osteo) with BMD	before X-ray	0.54	0.38–0.69	0.62	0.43–0.82	0.69	0.30–1.00
	after X-ray	0.72	0.60–0.84	0.70	0.55–0.84	0.95	0.84–1.00

ROC: receiver operating characteristic; AUC: area under the curve; CI: confidence interval.
BMD: Bone mineral density; Osteo: osteoporotic.